Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.

Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.

Item

http://www.wikidata.org/entity/Q33232455

Q33232455

about

Advances in recombinant antibody manufacturing NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy Fc glycans of therapeutic antibodies as critical quality attributes Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics Targeting the Fc receptor in autoimmune disease Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucose Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity Rapid high yield production of different glycoforms of Ebola virus monoclonal antibody Intravital imaging reveals improved Kupffer cell-mediated phagocytosis as a mode of action of glycoengineered anti-CD20 antibodies Synthetic antibodies as therapeutics.Systems analysis of N-glycan processing in mammalian cells Double knockdown of alpha1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC Inhibition of HPA-1a alloantibody-mediated platelet destruction by a deglycosylated anti-HPA-1a monoclonal antibody in mice: toward targeted treatment of fetal-alloimmune thrombocytopenia.Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity IgG subclasses and allotypes: from structure to effector functions.Function characterization of a glyco-engineered anti-EGFR monoclonal antibody cetuximab in vitro.Characterization of N-Linked Glycosylation in a Monoclonal Antibody Produced in NS0 Cells Using Capillary Electrophoresis with Laser-Induced Fluorescence Detection Development of a cell-based assay measuring the activation of FcγRIIa for the characterization of therapeutic monoclonal antibodies Prophylactic anti-D preparations display variable decreases in Fc-fucosylation of anti-D.High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations.Enzymatic functionalization of a nanobody using protein insertion technology.Emerging technologies for making glycan-defined glycoproteins Processing of complex N-glycans in IgG Fc-region is affected by core fucosylation Production of α2,6-sialylated IgG1 in CHO cells Modifications of therapeutic proteins: challenges and prospects.Antibody therapeutics: isotype and glycoform selection.What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins.Anti-infective antibodies: a novel tool to prevent and treat nosocomial diseases.Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans.Changes in fucosylation of human seminal IgG and secretory component of IgA in leukocytospermic patients.Aglycosylated antibodies and the methods of making and using them: WO2008030564.Antibody engineering to develop new antirheumatic therapies.Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.A novel baculovirus vector for the production of nonfucosylated recombinant glycoproteins in insect cells Production of therapeutic antibodies with controlled fucosylation.Engineering mammalian cells in bioprocessing - current achievements and future perspectives.Integrated approach toward the discovery of glyco-biomarkers of inflammation-related diseases.Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond.Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach.

P2860

Q26764949-1E1F87F6-C938-4CA3-BE7B-ED3E766E15BB Q26797345-B8EBA17A-62EE-4F1D-ADF5-8343C2136C05 Q26799266-452ADE1B-EBE7-47CD-82A0-C43CB10426C1 Q26849243-982B439B-8A86-422D-84B4-0F9315BF2910 Q27002843-CD9CF1E8-6427-49FF-A711-D6987E3162A9 Q27670877-F59C83AE-B7F4-46B7-A819-7A51F1FAD18D Q28069362-3D9F7678-66FF-46B9-8C49-5A2A4B92A7AB Q28658712-2C0FBB42-5A71-4749-B3F2-D326F994F752 Q28743509-5F5389C2-CA24-4CA7-9083-9AF31033DEDF Q30818421-5D62332F-CDCB-4045-879D-87830599F2B3 Q33265617-6B2359AA-2BC5-4D0B-B133-951179AF72AE Q33293527-98B7B1AA-49FB-4BBE-8FA7-A0A33542EECC Q33307815-BB9A7FD0-80BC-4F51-9941-2D1F0F302EA5 Q33407495-17DA42E8-4D22-4946-BF75-4FAE873478E5 Q33896738-3529355C-281E-4BBD-9EFC-D5CF2F985EEE Q34368678-D2E4474E-6D1B-4CA5-9254-782D39A712B1 Q34451930-A130A796-9035-4648-9B98-6AA5143A68F7 Q35052763-42343DC6-8395-4F14-A8C6-73E6E626DE13 Q35154170-1284A065-2DC2-49A7-B8F4-CBB124F1C6EF Q35262648-952656A8-DD24-47C4-9042-01E1F0AB396E Q35497686-6966B0EF-DE82-48E3-8BAC-B5706744E080 Q35597176-100D0D00-C526-4A3B-9E31-A5A38C8515AD Q35685635-3A4CD0E4-8A93-4959-B294-8F067BC29EED Q36211489-CF3F8F86-597A-414A-99EF-8D15504FBFD0 Q36213335-BB3A0FBB-11F4-434C-8595-870CF92F5D56 Q36495973-AB59D578-F219-4658-A51D-BD28024DC66A Q36922260-AF2DA06F-EA4B-4106-8540-A0C4B0C8E664 Q37034475-7BEF0F84-7230-48EE-8666-EFE3E0E2B720 Q37077611-C718492B-85D2-4CAC-9C59-6B0293CF78B0 Q37461186-CC91CCF7-F3B7-4B78-B0E9-424769223FB5 Q37480161-39CF1AD1-794A-44BF-ADA0-23AB866ED505 Q37481248-15A2A881-6068-4D9F-B229-8BDF30AC18FC Q37505420-607290CD-055E-4051-A800-A74D22B2E1C2 Q37563516-906D1501-2ED9-4599-B299-89D480D33A66 Q37573768-4A0C045E-68D7-4A00-9268-AEA5C9EBBF92 Q37672128-8DB06D2D-E949-41AA-B9B0-EADCB9BB73B9 Q37730868-EE27CF9C-17DA-4CD8-BF66-22D4A3636DC9 Q37989564-058ED247-FC9F-4275-8FA7-9DD344BDF498 Q37998314-3B475E66-057D-4E08-9A76-AB58DF38B32A Q37999739-0F310DAD-5A4F-4207-A9F3-1DBD507190EB

P2860

Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.

Item

http://www.wikidata.org/entity/Q33232455

description

2006 nî lūn-bûn

@nan

2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu